So the primary endpoint was too short for complete resolution of ALL clinical signs of aGVHD.
What matters is LT survival rates when the mortality rate is around 80%.
You know mortality, when people get to live or die?
Inverting the death rate by remestemcel-L is impressive surely even you understand that.
Deaths are to be avoided right?
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-154
-
- There are more pages in this discussion • 209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |